The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Tolerability and effectiveness of fulvestrant as first-line endocrine therapy in unselected patients with advanced breast cancer (ABC): Results of a multicenter, single arm, non-interventional study.
 
Yannan Zhao
No Relationships to Disclose
 
Cuizhi Geng
No Relationships to Disclose
 
Hongwei Zhang
No Relationships to Disclose
 
Li Cai
No Relationships to Disclose
 
Herui Yao
No Relationships to Disclose
 
Ying Lin
No Relationships to Disclose
 
Jianxia Liu
No Relationships to Disclose
 
Jin Yang
No Relationships to Disclose
 
Jin Zhang
No Relationships to Disclose
 
Xiaojia Wang
No Relationships to Disclose
 
Yafen Li
No Relationships to Disclose
 
Danmei Pang
No Relationships to Disclose
 
Tao Sun
No Relationships to Disclose
 
Xi Wang
No Relationships to Disclose
 
Jie Ma
No Relationships to Disclose
 
Aimin Zang
No Relationships to Disclose
 
Zhengyang Xu
No Relationships to Disclose
 
Yongsheng Wang
No Relationships to Disclose
 
Chuan Wang
No Relationships to Disclose
 
Xichun Hu
Honoraria - AstraZeneca; Daiichi Sankyo/Lilly; Eisai; Hengrui Pharmaceutical; Lilly; Merck; Novartis; Pfizer; Roche
Consulting or Advisory Role - AstraZeneca